10 trials match your filters.
| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831NCT03201757 | Alkermes, Inc. | Phase 3 | Completed | 2023-09-06Actual |
| Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsNCT04987229 | Alkermes, Inc. | Phase 3 | Enrolling by invitation | 2027-09Estimated |
| Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderNCT05303064 | Alkermes, Inc. | Phase 3 | Recruiting | 2027-12Estimated |
| A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)NCT06358950 | Alkermes, Inc. | Phase 2 | Completed | 2025-06-19Actual |
| A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2NCT06555783 | Alkermes, Inc. | Phase 2 | Completed | 2025-11-11Actual |
| A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaNCT06767683 | Alkermes, Inc. | Phase 2, Phase 3 | Recruiting | 2030-06Estimated |
| A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaNCT06843590 | Alkermes, Inc. | Phase 2 | Active not recruiting | 2026-11Estimated |
| A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1NCT07455383 | Alkermes, Inc. | Phase 3 | Recruiting | 2027-05Estimated |
| A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2NCT07502443 | Alkermes, Inc. | Phase 3 | Recruiting | 2027-05Estimated |
| A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)NCT07540897 | Alkermes, Inc. | Phase 3 | Recruiting | 2027-06Estimated |
Trial details
- Registry ID
- NCT03201757
- Phase
- Phase 3
Trial details
- Registry ID
- NCT04987229
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05303064
- Phase
- Phase 3
Trial details
- Registry ID
- NCT06358950
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06555783
- Phase
- Phase 2
Trial details
- Registry ID
- NCT06767683
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT06843590
- Phase
- Phase 2
Trial details
- Registry ID
- NCT07455383
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07502443
- Phase
- Phase 3
Trial details
- Registry ID
- NCT07540897
- Phase
- Phase 3
Primary completion marks the end of data collection for the main study measures, not a results publication date.